Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
KLK2 is a serine protease produced by secretory epithelial cells in the prostate (1). It is a glandular kallikrein that cleaves Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin (2). KLK2 can activate the proforms of PSA (prostate-specific antigen) and urokinase type plasminogen activator and inactivate plasminogen activator inhibitor-1, suggesting a possible role in a proteolytic cascade associated with prostate cancer. Thus, it may promote tumor growth, and metastasis and inhibition of KLK2 activity may, therefore, slow down tumor spread (1).
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
